A blended approach offers hope, but it could backfire and leave patients dependant on weight-loss medication, a critic warns.
Medications like semaglutide and tirzepatide are now recommended as a first-line treatment for managing cardiovascular disease risk among patients with obesity, marking continued clinical momentum for modern weight loss drugs.
The American College of Cardiology recently published the new guidelines, which square off those concerned about the ticking clock of heart attacks, stroke, and heart failure, against doctors in favor of a traditional approach of lifestyle changes before drugs. This represents a major pivot in the treatment of obesity related to heart disease risk.
